Home/Filings/4/0001479290-21-000038
4//SEC Filing

Rankin Aubrey 4

Accession 0001479290-21-000038

CIK 0001479290other

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 9:16 PM ET

Size

8.9 KB

Accession

0001479290-21-000038

Insider Transaction Report

Form 4
Period: 2021-02-02
Rankin Aubrey
DirectorPresident, Innovation & Tech
Transactions
  • Award

    Common Stock

    2021-02-02+11,90579,776 total
  • Award

    Employee Stock Option (Right to Buy)

    2021-02-02+21,54021,540 total
    Exercise: $28.01Exp: 2031-02-01Common Stock (21,540 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    174,302
  • Common Stock

    (indirect: By Trust)
    444,446
Footnotes (4)
  • [F1]The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from March 15, 2021, subject to Mr. Rankin's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
  • [F2]These shares are held by The Rankin Irrevocable Trust. Mr. Rankin is a Trustee of the Rankin Irrevocable Trust.
  • [F3]These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.
  • [F4]The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2021, subject to Mr. Rankin's Continuous Service (as defined in the Plan) on each vesting date.

Issuer

Revance Therapeutics, Inc.

CIK 0001479290

Entity typeother

Related Parties

1
  • filerCIK 0001818576

Filing Metadata

Form type
4
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 9:16 PM ET
Size
8.9 KB